As N‐cadherin antagonists have been shown to overcome bone marrow stromal cell‐mediated resistance to chemotherapeutic agents in chronic myeloid leukemia cells,88, 89 we therefore cannot exclude the possibility that LCRF‐0006 treatment may disrupt MM tumor cell interactions with the supportive bone marrow niche in vivo, thereby increasing tumor cell sensitivity to bortezomib. The gene discussed is CDH2; the disease is neoplasm.